

L Number	Hits	Search Text	DB	Time stamp
1	1465063	composition	USPAT; US-PGPUB; EPO; DERWENT	2003/02/24 09:14
2	36059	composition and (odor or malodor or odour or malodour)	USPAT; US-PGPUB; EPO; DERWENT	2003/02/24 09:14
3	904	(composition and (odor or malodor or odour or malodour)) and cyclodextrin	USPAT; US-PGPUB; EPO; DERWENT	2003/02/24 09:14
4	510	((composition and (odor or malodor or odour or malodour)) and cyclodextrin) and surfactant	USPAT; US-PGPUB; EPO; DERWENT	2003/02/24 09:15
5	369	((composition and (odor or malodor or odour or malodour)) and cyclodextrin) and surfactant) and (low and degree)	USPAT; US-PGPUB; EPO; DERWENT	2003/02/24 09:15
6	321	((((composition and (odor or malodor or odour or malodour)) and cyclodextrin) and surfactant) and (low and degree)) and substitut\$	USPAT; US-PGPUB; EPO; DERWENT	2003/02/24 09:15
7	281	(((((composition and (odor or malodor or odour or malodour)) and cyclodextrin) and surfactant) and (low and degree)) and substitut\$) and (alkyl or hydroxyalkyl)	USPAT; US-PGPUB; EPO; DERWENT	2003/02/24 09:16
8	280	(((((composition and (odor or malodor or odour or malodour)) and cyclodextrin) and surfactant) and (low and degree)) and substitut\$) and (alkyl or hydroxyalkyl)) and (spray or surface or inanimate or dry)	USPAT; US-PGPUB; EPO; DERWENT	2003/02/24 09:17
9	260	(((((composition and (odor or malodor or odour or malodour)) and cyclodextrin) and surfactant) and (low and degree)) and substitut\$) and (alkyl or hydroxyalkyl)) and (spray or surface or inanimate or dry)) and (alpha or beta or gamma)	USPAT; US-PGPUB; EPO; DERWENT	2003/02/24 09:17
10	186	((((((composition and (odor or malodor or odour or malodour)) and cyclodextrin) and surfactant) and (low and degree)) and substitut\$) and (alkyl or hydroxyalkyl)) and (spray or surface or inanimate or dry)) and (alpha or beta or gamma)) and (compatible or incompatible)	USPAT; US-PGPUB; EPO; DERWENT	2003/02/24 09:18

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal623kxg

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock  
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area  
NEWS 4 Apr 09 ZDB will be removed from STN  
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB  
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS  
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER  
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available  
NEWS 9 Jun 03 New e-mail delivery for search results now available  
NEWS 10 Jun 10 MEDLINE Reload  
NEWS 11 Jun 10 PCTFULL has been reloaded  
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment  
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;  
saved answer sets no longer valid  
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY  
NEWS 15 Jul 30 NETFIRST to be removed from STN  
NEWS 16 Aug 08 CANCERLIT reload  
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN  
NEWS 18 Aug 08 NTIS has been reloaded and enhanced  
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)  
now available on STN  
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded  
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded  
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced  
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced  
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file  
NEWS 25 Sep 16 CA Section Thesaurus available in CAPLUS and CA  
NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985  
NEWS 27 Oct 21 EVENTLINE has been reloaded  
NEWS 28 Oct 24 BEILSTEIN adds new search fields  
NEWS 29 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN  
NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002  
NEWS 31 Nov 18 DKILIT has been renamed APOLLIT  
NEWS 32 Nov 25 More calculated properties added to REGISTRY  
NEWS 33 Dec 02 TIBKAT will be removed from STN  
NEWS 34 Dec 04 CSA files on STN  
NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date  
NEWS 36 Dec 17 TOXCENTER enhanced with additional content  
NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN  
NEWS 38 Dec 30 ISMEC no longer available  
NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPLUS  
NEWS 40 Jan 21 NUTRACEUT offering one free connect hour in February 2003  
NEWS 41 Jan 21 PHARMAML offering one free connect hour in February 2003  
NEWS 42 Jan 29 Simultaneous left and right truncation added to COMPENDEX,  
ENERGY, INSPEC  
NEWS 43 Feb 13 CANCERLIT is no longer being updated  
  
NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,

CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 07:33:34 ON 24 FEB 2003

=> file polymers		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'APOLLIT' ENTERED AT 07:33:47 ON 24 FEB 2003  
COPYRIGHT (c) 2003 FIZ Karlsruhe

FILE 'BABS' ENTERED AT 07:33:47 ON 24 FEB 2003  
COPYRIGHT (c) 2003 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften  
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'CAPLUS' ENTERED AT 07:33:47 ON 24 FEB 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 07:33:47 ON 24 FEB 2003  
COPYRIGHT (c) 2003 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CEN' ENTERED AT 07:33:47 ON 24 FEB 2003  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 07:33:47 ON 24 FEB 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'EMA' ENTERED AT 07:33:47 ON 24 FEB 2003  
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 07:33:47 ON 24 FEB 2003  
COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 07:33:47 ON 24 FEB 2003  
COPYRIGHT (C) 2003 Japan Science and Technology Corporation (JST)

FILE 'PASCAL' ENTERED AT 07:33:47 ON 24 FEB 2003  
Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'PLASNEWS' ENTERED AT 07:33:47 ON 24 FEB 2003  
Copyright (C) 2003 Bill Communications, Inc. (BCI)

FILE 'PROMT' ENTERED AT 07:33:47 ON 24 FEB 2003  
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 07:33:47 ON 24 FEB 2003  
COPYRIGHT (C) 2003 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 07:33:47 ON 24 FEB 2003  
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'TEXTILETECH' ENTERED AT 07:33:47 ON 24 FEB 2003  
COPYRIGHT (C) 2003 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 07:33:47 ON 24 FEB 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 07:33:47 ON 24 FEB 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPINDEX' ENTERED AT 07:33:47 ON 24 FEB 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WTEXTILES' ENTERED AT 07:33:47 ON 24 FEB 2003  
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

=> composition  
COMPOSITION IS NOT A RECOGNIZED COMMAND  
The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> s composition  
16 FILES SEARCHED...  
L1 4548373 COMPOSITION

=> s l1 and cyclodextrin  
L2 12915 L1 AND CYCLODEXTRIN

=> s l2 and (substitution and degree)  
18 FILES SEARCHED...  
L3 2457 L2 AND (SUBSTITUTION AND DEGREE)

=> s l3 and (alkyl or hydroxyalkyl)  
L4 1850 L3 AND (ALKYL OR HYDROXYALKYL)

=> s l4 and (alpha or beta or gamma)  
15 FILES SEARCHED...  
L5 1766 L4 AND (ALPHA OR BETA OR GAMMA)

=> s l5 and (captur? or odor or malodor)  
L6 621 L5 AND (CAPTUR? OR ODOR OR MALODOR)

=> s l6 and (process or manufactur? or method or making)  
10 FILES SEARCHED...  
16 FILES SEARCHED...  
18 FILES SEARCHED...  
L7 621 L6 AND (PROCESS OR MANUFACTUR? OR METHOD OR MAKING)

=> s l7 and (surfactant or compatible or incompatible)  
L8 548 L7 AND (SURFACTANT OR COMPATIBLE OR INCOMPATIBLE)

=> s 18 and mixture  
L9 540 L8 AND MIXTURE

=> s 19 and (micelle or vescile).  
L10 64 L9 AND (MICELLE OR VESCILE)

=> s 110 and (surface or apply or dry)  
16 FILES SEARCHED...  
L11 64 L10 AND (SURFACE OR APPLY OR DRY)

=> dis 111 1-64 bib abs

L11 ANSWER 1 OF 64 IFIPAT COPYRIGHT 2003 IFI  
AN 10055921 IFIPAT;IFIUDB;IFICDB  
TI **COMPOSITIONS** COMPRISING **CYCLODEXTRIN** DERIVATIVES;  
LOW-DEGREE OF SUBSTITUTION **CYCLODEXTRIN**  
DERIVATIVES SUCH AS **HYDROXYALKYL CYCLODEXTRIN**,  
ALKYLATED **CYCLODEXTRIN**, FOR REMOVING UNWANTED MOLECULES FROM A  
**SURFACE**, DEODORIZING  
INF DuVal; Dean Larry, Lebanon, OH, US  
Reece; Steven, West Chester, OH, US  
Schaeffer; Heather Ann, Loveland, OH, US  
Uchiyama; Hirotaka, Symmes Twp, OH, US  
Woo; Ricky Ah-Man, Hamilton, OH, US  
IN DuVal Dean Larry; Reece Steven; Schaeffer Heather Ann; Uchiyama Hirotaka;  
Woo Ricky Ah-Man  
PAF Unassigned  
PA Unassigned Or Assigned To Individual (68000)  
AG THE PROCTER & GAMBLE COMPANY PATENT DIVISION, IVORYDALE TECHNICAL  
CENTER-BOX 474, 5299 SPRING GROVE AVENUE, CINCINNATI, OH, 45217, US  
PI US 2001056080 A1 20011227  
AI US 2001-855329 20010515  
PRAI US 2000-204164P 20000515 (Provisional)  
FI US 2001056080 20011227  
DT Utility; Patent Application - First Publication  
FS CHEMICAL  
APPLICATION  
CLMN 16  
AB A stable **composition** for removing unwanted molecules from a  
**surface** comprises low-degree of **substitution**  
**cyclodextrin** derivatives. The **compositions** are suitable  
for **capturing** unwanted molecules from inanimate  
**surfaces**, including fabrics, including carpets, and household  
**surfaces** such as countertops, dishes, floors, garbage cans,  
ceilings, walls, carpet padding, air filters, and the like, and from  
animate **surfaces**, including skin, hair, and the like. The  
**compositions** can further comprise **cyclodextrin-**  
**compatible** and **-incompatible** materials, and other  
optional ingredients.  
CLMN 16

L11 ANSWER 2 OF 64 PROMT COPYRIGHT 2003 Gale Group  
AN 2001:268760 PROMT  
TI A Perspective on the History of and Current Research in **Surfactant**  
-Modified, Water-Soluble Polymers.  
AU Glass, J. Edward  
SO The Journal of Coatings Technology, (Feb 2001) Vol. 73, No. 913, pp. 79.  
ISSN: 0361-8773.  
PB Federation of Societies for Coatings Technology  
DT Newsletter  
LA English  
WC 15677

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

AB North Dakota State University [\*]

THIS IS THE FULL TEXT: COPYRIGHT 2001 Federation of Societies for Coatings Technology

Subscription: \$40.00 per year. Published monthly. 492 Norristown Road, Blue Bell, PA 19422.

L11 ANSWER 3 OF 64 USPATFULL

AN 2003:51206 USPATFULL

TI Novel PN9826 nucleic acids and use thereof

IN Wettstein, Daniel Albert, Salt Lake City, UT, UNITED STATES

Mauck, Kimberly A., Sandy, UT, UNITED STATES

PA Myriad Genetics, Incorporated, Salt Lake City, UT, UNITED STATES, 84108 (U.S. corporation)

PI US 2003036163 A1 20030220

AI US 2002-195142 A1 20020710 (10)

PRAI US 2001-304323P 20010710 (60)

DT Utility

FS APPLICATION

LREP MYRIAD GENETICS INC., LEGAL DEPARTMENT, 320 WAKARA WAY, SALT LAKE CITY, UT, 84108

CLMN Number of Claims: 30

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 5944

AB Novel PN9826 protein and nucleic acids encoding PN9826 are provided. PN9826-containing protein complexes formed by PN9826 and a PN9826-interacting protein (e.g., LTBP1) are also provided. LTBP1 and PN9826 may be involved in common biological **processes** such as angiogenesis, metastasis, and cell growth and adhesion. Thus, the protein complexes as well as PN9826 can be used in screening assays to select modulators of PN9826 and the protein complexes formed by PN9826 and LTBP1. The identified modulators can be useful in modulating the functions and activities of PN9826 and protein complexes containing PN9826.

L11 ANSWER 4 OF 64 USPATFULL

AN 2003:47498 USPATFULL

TI **Methods** of imaging and treatment with targeted **compositions**

IN Unger, Evan C., Tucson, AZ, United States

Wu, Yunqiu, Tucson, AZ, United States

PA Bristol-Myers Squibb Medical Imaging, Inc., Princeton, NJ, United States (U.S. corporation)

PI US 6521211 B1 20030218

AI US 1999-243640 19990203 (9)

RLI Continuation-in-part of Ser. No. US 1998-218660, filed on 22 Dec 1998  
Continuation-in-part of Ser. No. US 1996-660032, filed on 6 Jun 1996, now abandoned  
Continuation-in-part of Ser. No. US 1996-640464, filed on 1 May 1996, now abandoned  
Continuation-in-part of Ser. No. US 1995-497684, filed on 7 Jun 1995, now abandoned

PRAI US 1998-73913P 19980206 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Travers, Russell; Assistant Examiner: Sharareh, Shahnam

LREP Woodcock Washburn LLP

CLMN Number of Claims: 58

ECL Exemplary Claim: 1

DRWN 17 Drawing Figure(s); 12 Drawing Page(s)

LN.CNT 7580

AB Novel ultrasound **methods** comprising administering to a patient

a targeted vesicle **composition** which comprises vesicles comprising a lipid, protein or polymer, encapsulating a gas, in combination with a targeting ligand, and scanning the patient using ultrasound. The scanning may comprise exposing the patient to a first type of ultrasound energy and then interrogating the patient using a second type of ultrasound energy. The targeting ligand preferably targets tissues, cells or receptors, including myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIbIIIa receptor. The **methods** may be used to detect a thrombus, enhancement of an old or echogenic thrombus, low concentrations of vesicles and vesicles targeted to tissues, cells or receptors.

L11 ANSWER 5 OF 64 USPATFULL

AN 2003:37603 USPATFULL

TI Human cDNAs and proteins and uses thereof

IN Bejanin, Stephane, Paris, FRANCE

Tanaka, Hiroaki, Antony, FRANCE

PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)

PI US 2003027248 A1 20030206

AI US 2001-924340 A1 20010806 (9)

PRAI US 2001-305456P 20010713 (60)

US 2001-302277P 20010629 (60)

US 2001-298698P 20010615 (60)

US 2001-293574P 20010525 (60)

DT Utility

FS APPLICATION

LREP GENSET, JOHN LUCAS, PHD, J.D., 10665 SORRENTO VALLEY RD, SAN DIEGO, CA, 92121

CLMN Number of Claims: 13

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 25650

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L11 ANSWER 6 OF 64 USPATFULL

AN 2003:37544 USPATFULL

TI Salicylamide-lanthanide complexes for use as luminescent markers

IN Raymond, Kenneth N., Berkeley, CA, UNITED STATES

Petoud, Stephane, Berkeley, CA, UNITED STATES

Cohen, Seth, Boston, MA, UNITED STATES

Xu, Jide, Berkeley, CA, UNITED STATES

PA The Regents of the University of California, Oakland, CA, UNITED STATES (U.S. corporation)

PI US 2003027189 A1 20030206

AI US 2002-165818 A1 20020607 (10)

RLI Division of Ser. No. US 2000-507599, filed on 18 Feb 2000, GRANTED, Pat. No. US 6406297

PRAI WO 2000-US4284 20000218

US 1999-120600P 19990218 (60)

DT Utility

FS APPLICATION

LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

CLMN Number of Claims: 112

ECL Exemplary Claim: 1

DRWN 12 Drawing Page(s)

LN.CNT 3616

AB The present invention provides luminescent lanthanide metal chelates comprising a metal ion of the lanthanide series and a complexing agent comprising at least one salicylamidyl moiety. Also provided are probes incorporating the salicylamidyl ligands of the invention and **methods** utilizing the ligands of the invention and probes comprising the ligands of the invention.

L11 ANSWER 7 OF 64 USPATFULL

AN 2003:37516 USPATFULL

TI Human cDNAs and proteins and uses thereof

IN Bejanin, Stephane, Paris, FRANCE

Tanaka, Hiroaki, Antony, FRANCE

PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)

PI US 2003027161 A1 20030206

AI US 2001-992600 A1 20011113 (9)

RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING

PRAI WO 2001-IB1715 20010806

US 2001-305456P 20010713 (60)

US 2001-302277P 20010629 (60)

US 2001-298698P 20010615 (60)

US 2001-293574P 20010525 (60)

DT Utility

FS APPLICATION

LREP John Lucas, Ph.D., J.D., GENSET CORP., 10665 Sorrento Valley Road, San Diego, CA, 92121-1609

CLMN Number of Claims: 13

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 25529

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

L11 ANSWER 8 OF 64 USPATFULL

AN 2003:30383 USPATFULL

TI APOA2-interacting proteins and use thereof

IN Bartel, Paul, Salt Lake City, UT, UNITED STATES

Sugiyama, Janice, Salt Lake City, UT, UNITED STATES

PA Myriad Genetics, Incorporated, Salt Lake City, UT (U.S. corporation)

PI US 2003022330 A1 20030130

AI US 2002-125639 A1 20020418 (10)

PRAI US 2001-285324P 20010419 (60)

US 2002-349843P 20020117 (60)

DT Utility

FS APPLICATION

LREP MYRIAD GENETICS INC., LEGAL DEPARTMENT, 320 WAKARA WAY, SALT LAKE CITY, UT, 84108

CLMN Number of Claims: 38

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4780

AB Protein complexes are provided comprising APOA2 and one or more APOA2-interacting proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with APOA2 and its interacting partners. In



addition, **methods** of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

L11 ANSWER 9 OF 64 USPATFULL

AN 2003:18105 USPATFULL

TI Solid- and solution-phase synthesis of heparin and other glycosaminoglycans

IN Seeberger, Peter H., Cambridge, MA, UNITED STATES

Orgueira, Hernan, Cambridge, MA, UNITED STATES

Schell, Peter, Boston, MA, UNITED STATES

PI US 2003013862 A1 20030116

AI US 2002-54724 A1 20020122 (10)

PRAI US 2001-263621P 20010123 (60)

DT Utility

FS APPLICATION

LREP FOLEY HOAG LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BOULEVARD, BOSTON, MA, 02110-2600

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN 17 Drawing Page(s)

LN.CNT 4697

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described is a modular, general synthetic strategy for the preparation in solution and on a solid support of heparin, heparin-like glycosaminoglycans, glycosaminoglycans and non-natural analogs of each of them. Additionally, the modular strategy provides the basis for the preparation of combinatorial libraries and parallel libraries of defined glycosaminoglycan oligosaccharides. The defined glycosaminoglycan structures may be used in high-throughput screening experiments to identify carbohydrate sequences that regulate a host of recognition and signal-transduction **processes**. The determination of specific sequences involved in receptor binding holds great promise for the development of molecular tools which will allow modulation of **processes** underlying viral entry, angiogenesis, kidney diseases and diseases of the central nervous system. Notably, the present invention enables the automated synthesis of glycosaminoglycans in much the same fashion that peptides and oligonucleotides are currently assembled.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 10 OF 64 USPATFULL

AN 2003:10678 USPATFULL

TI APOA1-interacting proteins and use thereof

IN Bartel, Paul, Salt Lake City, UT, UNITED STATES

Szankasi, Philippe, Salt Lake City, UT, UNITED STATES

Sugiyama, Janice, Salt Lake City, UT, UNITED STATES

PA Myriad Genetics, Incorporated, Salt Lake City, UT (U.S. corporation)

PI US 2003008373 A1 20030109

AI US 2002-124767 A1 20020417 (10)

PRAI US 2001-284220P 20010417 (60)

US 2002-354899P 20020206 (60)

DT Utility

FS APPLICATION

LREP MYRIAD GENETICS INC., LEGAL DEPARTMENT, 320 WAKARA WAY, SALT LAKE CITY, UT, 84108

CLMN Number of Claims: 38

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4667

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Protein complexes are provided comprising APOA1 and one or more

APOA1-interacting proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with APOA1 and its interacting partners. In addition, **methods** of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 11 OF 64 USPATFULL

AN 2003:10629 USPATEFULL

TI Caspase-7-interacting protein and use thereof

IN Bartel, Paul, Salt Lake City, UT, UNITED STATES

PA Myriad Genetics, Incorporated, Salt Lake City, UT (U.S. corporation)

PI US 2003008324 A1 20030109

AI US 2002-124550 A1 20020417 (10)

PRAI US 2001-284404P 20010417 (60)

DT Utility

FS APPLICATION

LREP MYRIAD GENETICS INC., LEGAL DEPARTMENT, 320 WAKARA WAY, SALT LAKE CITY, UT, 84108

CLMN Number of Claims: 38

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4771

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Protein complexes are provided comprising Caspase-7 and a Caspase-7-interacting protein. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with Caspase-7 and the Caspase-7-interacting protein. In addition, **methods** for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 12 OF 64 USPATFULL

AN 2002:344628 USPATFULL

TI **Compositions** and **methods** for the detection, diagnosis and therapy of hematological malignancies

IN Gaiger, Alexander, Seattle, WA, UNITED STATES

Algate, Paul A., Issaquah, WA, UNITED STATES

Mannion, Jane, Seattle, WA, UNITED STATES

PI US 2002198362 A1 20021226

AI US 2001-796692 A1 20010301 (9)

PRAI US 2000-223378P 20000807 (60)

US 2000-223416P 20000804 (60)

US 2000-222903P 20000803 (60)

US 2000-218950P 20000714 (60)

US 2000-206201P 20000522 (60)

US 2000-202084P 20000504 (60)

US 2000-200999P 20000501 (60)

US 2000-200303P 20000428 (60)

US 2000-200779P 20000428 (60)

US 2000-200545P 20000427 (60)

US 2000-190479P 20000317 (60)

US 2000-186126P 20000301 (60)

DT Utility

FS APPLICATION

LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

CLMN Number of Claims: 100

ECL Exemplary Claim: 1

DRWN 5 Drawing Page(s)

LN.CNT 19014

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are **methods** and **compositions** for the detection, diagnosis, prognosis, and therapy of hematological malignancies, and in particular, human leukemias and lymphomas of the follicular, Hodgkin's and B cell and T cell non-Hodgkin's types. Disclosed are **compositions**, **methods** and kits for eliciting immune and T cell responses to specific malignancy-related antigenic polypeptides and antigenic polypeptide fragments thereof in an animal. Also disclosed are **compositions** and **methods** for use in the identification of cells and biological samples containing one or more hematological malignancy-related **compositions**, and **methods** for the detection and diagnosis of such diseases and affected cell types. Also disclosed are diagnostic and therapeutic kits, as well as **methods** for the diagnosis, therapy and/or prevention of a variety of leukemias and lymphomas.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 13 OF 64 USPATFULL

AN 2002:343965 USPATFULL

TI FLT4-interacting proteins and use thereof

IN Sugiyama, Janice, Salt Lake City, UT, UNITED STATES

PA Myriad Genetics, Incorporated, Salt Lake City, UT, UNITED STATES (U.S. corporation)

PI US 2002197691 A1 20021226

AI US 2002-135802 A1 20020429 (10)

PRAI US 2001-287513P 20010430 (60)

DT Utility

FS APPLICATION

LREP MYRIAD GENETICS INC., LEGAL DEPARTMENT, 320 WAKARA WAY, SALT LAKE CITY, UT, 84108

CLMN Number of Claims: 38

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4778

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Protein complexes are provided comprising FLT4 and one or more FLT4-interacting proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with FLT4 and its interacting partners. In addition, **methods** of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 14 OF 64 USPATFULL

AN 2002:330424 USPATFULL

TI Phthalamide lanthanide complexes for use as luminescent markers

IN Raymond, Kenneth N., Berkeley, CA, UNITED STATES

Petoud, Stephane, Berkeley, CA, UNITED STATES

Cohen, Seth, Boston, MA, UNITED STATES

Xu, Jide, Berkeley, CA, UNITED STATES

PI US 2002188111 A1 20021212

US 6515113 B2 20030204

AI US 2000-507630 A1 20000218 (9)

PRAI US 1999-120881P 19990218 (60)

DT Utility

FS APPLICATION

LREP Jeffry S Mann, Townsend And Townsend And Crew LLP, Two Embarcadero

Center 8th Floor, San Francisco, CA, 94111-3834

CLMN Number of Claims: 123

ECL Exemplary Claim: 1

DRWN 23 Drawing Page(s)

LN.CNT 4409

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides luminescent lanthanide metal chelates comprising a metal ion of the lanthanide series and a complexing agent comprising at least one phthalamidyl moiety. Also provided are probes incorporating the phthalamidyl ligands of the invention and **methods** utilizing the ligands of the invention and probes comprising the ligands of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 15 OF 64 USPATFULL

AN 2002:315203 USPATFULL

TI BCL-XL-interacting protein and use thereof

IN Bartel, Paul, Salt Lake City, UT, UNITED STATES

PA Myriad Genetics, Incorporated, Salt Lake City, UT, UNITED STATES, 84108  
(U.S. corporation)

PI US 2002177692 A1 20021128

AI US 2002-122573 A1 20020415 (10)

PRAI US 2001-284095P 20010416 (60)

DT Utility

FS APPLICATION

LREP MYRIAD GENETICS INC., LEGAL DEPARTMENT, 320 WAKARA WAY, SALT LAKE CITY,  
UT, 84108

CLMN Number of Claims: 38

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 4757

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Protein complexes are provided comprising BCL-XL and TCTP. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with BCL-XL and TCTP. In addition, **methods** for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 16 OF 64 USPATFULL

AN 2002:315121 USPATFULL

TI 4,4-Disubstituted piperidines, and **methods** of use thereof

IN Hoemann, Michael Z., Marlborough, MA, UNITED STATES

PI US 2002177607 A1 20021128

AI US 2001-12182 A1 20011204 (10)

PRAI US 2000-251651P 20001206 (60)

DT Utility

FS APPLICATION

LREP FOLEY HOAG LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT  
BOULEVARD, BOSTON, MA, 02110-2600

CLMN Number of Claims: 91

ECL Exemplary Claim: 1

DRWN 7 Drawing Page(s)

LN.CNT 2998

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine transporters. The compounds of the present invention will find use in the treatment of numerous ailments,

conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhan disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 17 OF 64 USPATFULL  
AN 2002:314730 USPATFULL  
TI Tsg101-interacting proteins and use thereof  
IN Sugiyama, Janice, Salt Lake City, UT, UNITED STATES  
Cimbora, Daniel, Salt Lake City, UT, UNITED STATES  
PA Myriad Genetics, Incorporated, Salt Lake City, UT, UNITED STATES, 84108  
(U.S. corporation)  
PI US 2002177207 A1 20021128  
AI US 2002-98979 A1 20020314 (10)  
PRAI US 2001-276259P 20010314 (60)  
US 2001-304101P 20010710 (60)  
DT Utility  
FS APPLICATION  
LREP MYRIAD GENETICS INC., LEGAL DEPARTMENT, 320 WAKARA WAY, SALT LAKE CITY,  
UT, 84108  
CLMN Number of Claims: 38  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 7034

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Protein complexes are provided comprising Tsg101 and one or more protein interactors of Tsg101. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with Tsg101 and its interacting partner proteins. In addition, **methods** of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 18 OF 64 USPATFULL  
AN 2002:314675 USPATFULL  
TI COX 1-interacting proteins and use thereof  
IN Wettstein, Daniel Albert, Salt Lake City, UT, UNITED STATES  
PA Myriad Genetics, Incorporated, Salt Lake City, UT (U.S. corporation)  
PI US 2002177152 A1 20021128  
AI US 2002-100503 A1 20020318 (10)  
PRAI US 2001-277013P 20010319 (60)  
DT Utility  
FS APPLICATION  
LREP MYRIAD GENETICS INC., LEGAL DEPARTMENT, 320 WAKARA WAY, SALT LAKE CITY,  
UT, 84108  
CLMN Number of Claims: 38  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 4721

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Protein complexes are provided comprising COX1 and one or more proteins

selected from the group consisting of THR S14 and Opal. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with COX1 and its interacting partner proteins. In addition, **methods** of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 19 OF 64 USPATFULL  
AN 2002:307902 USPATFULL  
TI Survivin-interacting proteins and use thereof  
IN Wettstein, Daniel Albert, Salt Lake City, UT, UNITED STATES  
Cimbora, Daniel, Salt Lake City, UT, UNITED STATES  
PA Myriad Genetics, Incorporated, Salt Lake City, UT (U.S. corporation)  
PI US 2002173026 A1 20021121  
AI US 2002-99924 A1 20020314 (10)  
PRAI US 2001-276179P 20010315 (60)  
US 2001-307233P 20010723 (60)  
DT Utility  
FS APPLICATION  
LREP MYRIAD GENETICS INC., LEGAL DEPARTMENT, 320 WAKARA WAY, SALT LAKE CITY,  
UT, 84108  
CLMN Number of Claims: 38  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 5137

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Protein complexes are provided comprising survivin and one or more proteins selected from the group consisting of HDLC1, **beta**-actin, DNA helicase II, COPP, OSTP, SLC8A1, A2-CAT. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with survivin and its interacting partner proteins. In addition, **methods** of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 20 OF 64 USPATFULL  
AN 2002:301545 USPATFULL  
TI Cleaning **composition**  
IN Foley, Peter Robert, Cincinnati, OH, UNITED STATES  
Hutton, Howard David, Oregonia, OH, UNITED STATES  
PI US 2002169090 A1 20021114  
AI US 2001-909288 A1 20010719 (9)  
PRAI US 2000-34907 20001221  
US 2000-34906 20001221  
US 2000-20255 20000725  
US 2000-19619 20000719  
US 2001-268487P 20010213 (60)  
DT Utility  
FS APPLICATION  
LREP THE PROCTER & GAMBLE COMPANY, INTELLECTUAL PROPERTY DIVISION, WINTON  
HILL TECHNICAL CENTER - BOX 161, 6110 CENTER HILL AVENUE, CINCINNATI,  
OH, 45224  
CLMN Number of Claims: 36  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1890

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A hard-surface cleaning **composition** for removing cooked-, baked-, or burnt-on food soil from cookware and tableware, the **composition** comprising a soil swelling agent and a thickening system comprising synthetic smectite type clay thickening agent having an average platelet size of less than about 100 nm. The **composition** has shear thinning properties and can be used as pre-treatment prior to the dishwashing **process**. The **composition** provides excellent removal of polymerized grease from metal and glass substrates.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 21 OF 64 USPATFULL  
AN 2002:283360 USPATFULL  
TI Keratinocyte derived interferon  
IN LaFleur, David W., Washington, DC, United States  
Moore, Paul A., Germantown, MD, United States  
Ruben, Steven M., Olney, MD, United States  
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)  
PI US 6472512 B1 20021029  
US 2002187950 A1 20021212  
AI US 2001-908594 20010720 (9)  
RLI Continuation-in-part of Ser. No. US 2000-487792, filed on 20 Jan 2000  
Continuation-in-part of Ser. No. WO 2000-US1239, filed on 20 Jan 2000  
Continuation-in-part of Ser. No. US 1999-358587, filed on 21 Jul 1999  
Continuation-in-part of Ser. No. WO 1999-US16424, filed on 21 Jul 1999  
Continuation-in-part of Ser. No. US 2001-358587, filed on 24 May 2001, now abandoned  
Continuation-in-part of Ser. No. WO 1998-US9916424, filed on 21 Jul 1998, now abandoned  
PRAI US 2001-292934P 20010524 (60)  
US 2000-219621P 20000721 (60)  
US 1998-93643P 19980721 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Kunz, Gary L.; Assistant Examiner: Seharaseyon, Jegatheesan  
LREP Human Genome Sciences, Inc.  
CLMN Number of Claims: 33  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Figure(s); 11 Drawing Page(s)  
LN.CNT 14148

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel KDI protein which is a member of the interferon family. In particular, isolated nucleic acid molecules are provided encoding a human interferon polypeptide, called "KDI". KDI polypeptides are also provided as are vectors, host cells and recombinant **methods** for producing the same. The invention further relates to screening **methods** for identifying agonists and antagonists of KDI activity. Also provided are therapeutic **methods** for treating immune system-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 22 OF 64 USPATFULL  
AN 2002:280646 USPATFULL  
TI Diazabicyclo[4.3.0]nonanes, and **methods** of use thereof  
IN Wu, Xinhe, Shrewsbury, MA, UNITED STATES  
PI US 2002156092 A1 20021024  
US 6476046 B2 20021105  
AI US 2001-21277 A1 20011030 (10)  
PRAI US 2000-251108P 20001204 (60)  
DT Utility

FS APPLICATION  
LREP FOLEY HOAG LLP, PATENT GROUP, 155 SEAPORT BOULEVARD, BOSTON, MA, 02110  
CLMN Number of Claims: 36  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 3080

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to diazabicyclo[4.3.0]nonanes. A second aspect of the present invention relates to the use of the diazabicyclo[4.3.0]nonanes as ligands for various cellular receptors, including opiate receptors. An additional aspect of the present invention relates to the use of the diazabicyclo[4.3.0]nonanes as analgesics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 23 OF 64 USPATFULL

AN 2002:266477 USPATFULL

TI Synthesis of 2-Hydroxymethylglutamic acid and congeners thereof

IN Kozikowski, Alan P., Princeton, NJ, UNITED STATES

PI US 2002147362 A1 20021010

AI US 2001-952325 A1 20010913 (9)

PRAI US 2000-232275P 20000913 (60)

DT Utility

FS APPLICATION

LREP FOLEY HOAG LLP, PATENT GROUP, 155 SEAPORT BOULEVARD, BOSTON, MA, 02110

CLMN Number of Claims: 35

ECL Exemplary Claim: 1

DRWN 2 Drawing Page(s)

LN.CNT 1922

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to 2-hydroxymethylglutamic acid and congeners thereof. A second aspect of the invention relates to a **method** of synthesizing 2-hydroxymethylglutamic acid and congeners thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 24 OF 64 USPATFULL

AN 2002:266257 USPATFULL

TI Compounds for targeting endothelial cells, **compositions** containing the same and **methods** for their use

IN Von Wronski, Mathew A., Moorestown, NJ, UNITED STATES

Marinelli, Edmund R., Lawrenceville, NJ, UNITED STATES

Nunn, Adrian D., Lambertville, NJ, UNITED STATES

Pillai, Radhakrishna, Cranbury, NJ, UNITED STATES

Ramalingam, Kondareddiar, Dayton, NJ, UNITED STATES

Tweedle, Michael F., Princeton, NJ, UNITED STATES

Linder, Karen, Kingston, NJ, UNITED STATES

Nanjappan, Palaniappa, Dayton, NJ, UNITED STATES

Raju, Natarajan, Kendall Park, NJ, UNITED STATES

PI US 2002147136 A1 20021010

AI US 2001-871974 A1 20010604 (9)

RLI Continuation-in-part of Ser. No. US 2000-585364, filed on 2 Jun 2000, PENDING

DT Utility

FS APPLICATION

LREP NIXON & VANDERHYE P.C., 8th Floor, 1100 North Glebe Road, Arlington, VA, 22201-4714

CLMN Number of Claims: 65

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 5017

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



AB The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, **compositions** containing the same and **methods** for their use. Additionally, the present invention includes diagnostic, therapeutic and radiotherapeutic **compositions** useful for visualization, therapy or radiotherapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 25 OF 64 USPATFULL  
AN 2002:265900 USPATFULL  
TI Compounds and **methods** for treatment and diagnosis of chlamydial infection  
IN Bhatia, Ajay, Seattle, WA, UNITED STATES  
Probst, Peter, Seattle, WA, UNITED STATES  
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)  
PI US 2002146776 A1 20021010  
AI US 2001-7693 A1 20011205 (10)  
RLI Continuation-in-part of Ser. No. US 2001-841260, filed on 23 Apr 2001, PENDING  
PRAI US 2000-219752P 20000720 (60)  
US 2000-198853P 20000421 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 4342

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and **methods** for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical **compositions** and vaccines comprising such polypeptides or DNA sequences are also provided, together with antibodies directed against such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of Chlamydial infection in patients and in biological samples.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 26 OF 64 USPATFULL  
AN 2002:236247 USPATFULL  
TI Phthalamide-lanthanide complexes for use as luminescent markers  
IN Raymond, Kenneth N., Berkeley, CA, UNITED STATES  
Petoud, Stephane, Berkeley, CA, UNITED STATES  
Cohen, Seth M., West Lake Village, CA, UNITED STATES  
Xu, Jide, Berkeley, CA, UNITED STATES  
PA Regents of UC Licensing Associate Office of Technology Licensing, Berkeley, CA, UNITED STATES, 94720-1620 (U.S. corporation)  
PI US 2002128451 A1 20020912  
AI US 2001-992156 A1 20011114 (9)  
RLI Division of Ser. No. US 2000-507630, filed on 18 Feb 2000, PENDING  
PRAI WO 2000-US4258 20000218  
US 1999-120881P 19990218 (60)  
US 1999-120600P 19990218 (60)  
DT Utility  
FS APPLICATION  
LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834  
CLMN Number of Claims: 123  
ECL Exemplary Claim: 1

DRWN 23 Drawing Page(s)

LN.CNT 4403

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides luminescent lanthanide metal chelates comprising a metal ion of the lanthanide series and a complexing agent comprising at least one phthalamidyl moiety. Also provided are probes incorporating the phthalamidyl ligands of the invention and **methods** utilizing the ligands of the invention and probes comprising the ligands of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 27 OF 64 USPATFULL

AN 2002:214180 USPATFULL

TI Halogenated calixpyrroles, calixpyridinopyrroles and calixpyridines, and uses thereof

IN Sessler, Jonathan L., Austin, TX, UNITED STATES

Marquez, Manuel, Lincolnshire, IL, UNITED STATES

Anzenbacher, Pavel, JR., Bowling Green, OH, UNITED STATES

Shriver, James A., Austin, TX, UNITED STATES

PI US 2002115566 A1 20020822

AI US 2001-939514 A1 20010824 (9)

RLI Continuation-in-part of Ser. No. US 2001-838998, filed on 20 Apr 2001, PENDING Division of Ser. No. US 1997-833379, filed on 4 Apr 1997, PATENTED

PRAI US 1996-14890P 19960405 (60)

US 1996-24203P 19960827 (60)

US 1996-26694P 19960925 (60)

US 1996-33395P 19961217 (60)

US 1996-33396P 19961217 (60)

DT Utility

FS APPLICATION

LREP AKIN GUMP STRAUSS HAUER & FELD, 1900 FROST BANK PLAZA, 816 CONGRESS AVENUE, AUSTIN, TX, 78701

CLMN Number of Claims: 30

ECL Exemplary Claim: 1

DRWN 44 Drawing Page(s)

LN.CNT 4874

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides halogenated calixpyrrole, calixpyridinopyrrole, and calixpyridine macrocycles having 4-12 pyrrolic rings with greater stability, enhanced anion and neutral molecule binding affinity, and different binding selectivities as compared to their nonhalogenated congeners as judged from <sup>1</sup>H NMR, <sup>19</sup>F NMR and fluorescence emission spectroscopic analyses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 28 OF 64 USPATFULL

AN 2002:209145 USPATFULL

TI **Process of manufacturing compositions** comprising **cyclodextrin**

IN Woo, Ricky Ah-Man, Hamilton, OH, United States

Uchiyama, Hirotaka, Loveland, OH, United States

DuVal, Dean Larry, Lebanon, OH, United States

Reece, Steven, West Chester, OH, United States

PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

PI US 6436442 B1 20020820

AI US 2000-570875 20000515 (9)

RLI Continuation-in-part of Ser. No. WO 1999-US27317, filed on 18 Nov 1999

PRAI US 1998-109834P 19981125 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Fubara, Blessing  
LREP Camp, Jason J., Zerby, Kim W., Miller, Steven W.  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 1831

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A **process** of **manufacturing** a **composition** suitable for **capturing** unwanted molecules comprising the steps of: (a) providing **cyclodextrin**, a **cyclodextrin-compatible** material, and a **cyclodextrin-incompatible** material; (b) combining said **cyclodextrin-compatible** material and said **cyclodextrin-incompatible** material to form a first **mixture**; and (c) subsequently combining said **cyclodextrin** with said first **mixture** to form said **composition** suitable for **capturing** unwanted molecules. The resulting stable **composition** for removing unwanted molecules from a **surface** comprises functionally-available **cyclodextrin** and **cyclodextrin-incompatible** material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 29 OF 64 USPATFULL  
AN 2002:202239 USPATFULL  
TI Keratinocyte derived interferon  
IN LaFleur, David W., Washington, DC, United States  
Moore, Paul A., Germantown, MD, United States  
Ruben, Steven M., Olney, MD, United States  
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)  
PI US 6433145 B1 20020813  
AI US 2000-487792 20000120 (9)  
RLI Continuation-in-part of Ser. No. US 1999-358587, filed on 21 Jul 1999, now abandoned Continuation-in-part of Ser. No. WO 1999-US16424, filed on 21 Jul 1999  
PRAI US 93643P (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Stucker, Jeffrey; Assistant Examiner: Seharaseyon, Jegatheesan  
LREP Human Genome Sciences, Inc.  
CLMN Number of Claims: 92  
ECL Exemplary Claim: 1  
DRWN 9 Drawing Figure(s); 9 Drawing Page(s)  
LN.CNT 13514

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel KDI protein which is a member of the interferon family. In particular, isolated nucleic acid molecules are provided encoding a human interferon polypeptide, called "KDI". KDI polypeptides are also provided as are vectors, host cells and recombinant **methods** for producing the same. The invention further relates to screening **methods** for identifying agonists and antagonists of KDI activity. Also provided are therapeutic **methods** for treating immune system-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 30 OF 64 USPATFULL  
AN 2002:157661 USPATFULL  
TI Therapeutic compounds for the treatment of asthma and allergy, and **methods** of use thereof  
IN Gao, Yun, Southborough, MA, UNITED STATES  
Rubin, Paul, Sudbury, MA, UNITED STATES

Xiaoyi, Nie, Boxborough, MA, UNITED STATES  
Zepp, Charles M., Hardwick, MA, UNITED STATES  
PI US 2002082268 A1 20020627  
AI US 2001-813096 A1 20010320 (9)  
PRAI US 2000-190620P 20000320 (60)  
DT Utility  
FS APPLICATION  
LREP FOLEY, HOAG & ELIOT, LLP, PATENT GROUP, ONE POST OFFICE SQUARE, BOSTON,  
MA, 02109  
CLMN Number of Claims: 35  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2753

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds capable of inhibiting leukotriene activity and histamine activity, and their use in treating asthma and allergic conditions such as hay fever, dermatitis, and urticaria. Inhibition of both pathways permits more effective treatment of conditions with fewer side effects than can be achieved using most available antihistamines alone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 31 OF 64 USPATFULL  
AN 2002:143599 USPATFULL  
TI Salicylamide-lanthanide complexes for use as luminescent markers  
IN Raymond, Kenneth N., Berkeley, CA, United States  
Petoud, Stephane, Berkeley, CA, United States  
Cohen, Seth, West Lake Village, CA, United States  
Xu, Jide, Berkeley, CA, United States  
PA The Regents of the University of California, Oakland, CA, United States  
(U.S. corporation)  
PI US 6406297 B1 20020618  
AI US 2000-507599 20000218 (9)  
PRAI US 1999-120600P 19990218 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Riley, Jezia  
LREP Townsend and Townsend and Crew LLP  
CLMN Number of Claims: 5  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)  
LN.CNT 3141

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides luminescent lanthanide metal chelates comprising a metal ion of the lanthanide series and a complexing agent comprising at least one salicylamidyl moiety. Also provided are probes incorporating the salicylamidyl ligands of the invention and **methods** utilizing the ligands of the invention and probes comprising the ligands of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 32 OF 64 USPATFULL  
AN 2002:126748 USPATFULL  
TI Antipsychotic sulfonamide-heterocycles, and **methods** of use thereof  
IN Wu, Xinhe, Shrewsbury, MA, UNITED STATES  
Aquila, Brian M., Marlborough, MA, UNITED STATES  
Shao, Liming, Lincoln, MA, UNITED STATES  
Radeke, Heike, S. Grafton, MA, UNITED STATES  
Cuny, Gregory D., Somerville, MA, UNITED STATES  
Hauske, James R., Concord, MA, UNITED STATES  
Xie, Roger L., Natick, MA, UNITED STATES

PI US 2002065265 A1 20020530  
AI US 2001-951137 A1 20010912 (9)  
PRAI US 2000-231607P 20000911 (60)  
DT Utility  
FS APPLICATION  
LREP FOLEY, HOAG & ELIOT, LLP, PATENT GROUP, ONE POST OFFICE SQUARE, BOSTON,  
MA, 02109  
CLMN Number of Claims: 120  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 3878

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to heterocyclic compounds comprising a sulfonamide moiety. A second aspect of the present invention relates to the use of the heterocyclic compounds comprising a sulfonamide moiety to treat diseases, afflictions or maladies caused at least in part by abnormal activity of one or more GPCRs or ligand-gated ion channels. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds comprising a sulfonamide moiety, and the screening of those libraries for biological activity, e.g., in animal models of psychosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 33 OF 64 USPATFULL  
AN 2002:122606 USPATFULL  
TI Fatty acids, soaps, **surfactant** systems, and consumer products based on branched 17-carbon fatty acids  
IN Connor, Daniel Stedman, The Procter & Gamble Company, Miami Valley Laboratories P.O. Box 538707, Cincinnati, OH, United States 45253-8707  
Scheibel, Jeffrey John, The Procter & Gamble Company, Miami Valley Laboratories P.O. Box 538707, Cincinnati, OH, United States 45253-8707  
Back, Deborah Jean, The Procter & Gamble Company, Sharon Woods Technical Center 11510 Reed Hartman Hwy., Cincinnati, OH, United States 45241  
Trinh, Toan, The Procter & Gamble Company, Sharon Woods Technical Center 11510 Reed Hartman Hwy., Cincinnati, OH, United States 45241  
Vinson, Phillip Kyle, The Procter & Gamble Company, Miami Valley Laboratories P.O. Box 538707, Cincinnati, OH, United States 45253-8707  
Severson, Roland George, The Procter & Gamble Company, Miami Laboratories P.O. Box 538707, Cincinnati, OH, United States 45253-8707  
Cripe, Thomas Anthony, The Procter & Gamble Company, Miami Valley Laboratories P.O. 538707, Cincinnati, OH, United States 45253-8707  
Burckett-St. Laurent, James Charles Theophile Roger, The Procter & Gamble Company, Miami Valley Laboratories P.O. Box 538707, Cincinnati, OH, United States 45253-8707  
Sivik, Mark Robert, The Procter & Gamble Company, Miami Valley Laboratories P.O. Box 538707, Cincinnati, OH, United States 45253-8707  
Wahl, Errol Hoffman, The Procter & Gamble Company, Sharon Woods Technical Center 11510 Reed Hartman Hwy., Cincinnati, OH, United States 45241  
Frankenbach, Gayle Marie, The Procter & Gamble Company, Sharon Woods Technical Center 11510 Reed Hartman Hwy., Cincinnati, OH, United States 45241  
Declercq, Marc Johan, Procter & Gamble Services Company, Temselaan 100, B-1853, Strombeek-Bever, BELGIUM  
Demeyere, Hugo Jean Marie, Procter & Gamble Services Company, Temselaan 100, B-1853, Strombeek-Bever, BELGIUM  
PI US 6395701 B1 20020528  
AI US 2000-507823 20000222 (9)  
PRAI US 1997-63603P 19971023 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Hardee, John  
LREP Cook, C. Brant, Zerby, Kim W., Miller, Steve W.

CLMN Number of Claims: 13  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 5457

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel fatty acids and derivatives thereof such as salts, new **surfactant** systems comprising one or more of these compounds, consumer products such as laundry products, personal care products, pharmaceutical **compositions**, industrial cleaners, and the like comprising said compounds or **surfactant** systems.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 34 OF 64 USPATFULL  
AN 2002:99107 USPATFULL  
TI Generation of combinatorial synthetic libraries and screening for proadhesins and nonadhesins  
IN Alberte, Randall S., Falmouth, ME, UNITED STATES  
Smith, Robert D., Falmouth, ME, UNITED STATES  
PI US 2002052003 A1 20020502  
AI US 2001-826287 A1 20010403 (9)  
PRAI US 2000-194333P 20000403 (60)  
DT Utility  
FS APPLICATION  
LREP FOLEY, HOAG & ELIOT, LLP, PATENT GROUP, ONE POST OFFICE SQUARE, BOSTON, MA, 02109  
CLMN Number of Claims: 40  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2739

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to compounds, comprising at least two moieties selected from the group consisting of aryl sulfonates and aryl sulfates. A second aspect of the present invention relates to combinatorial libraries of the aforementioned compounds. The present invention also relates to **compositions** comprising a compound of the present invention. A fourth aspect of the present invention relates to the use of a compound or **composition** of the present invention in a **method** for inhibiting bioadhesion to a **surface**. Another aspect of the present invention relates to the use of a compound or **composition** of the present invention in a **method** for enhancing bioadhesion to a **surface**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 35 OF 64 USPATFULL  
AN 2002:72842 USPATFULL  
TI Cleaning **composition**  
IN Foley, Peter Robert, Cincinnati, OH, UNITED STATES  
Hutton, Howard David, III, Oregonia, OH, UNITED STATES  
Kaiser, Carl-Eric, Mason, OH, UNITED STATES  
Zhu, Yong, Cincinnati, OH, UNITED STATES  
Pieroni, Lucio, Nishinomiya, JAPAN  
Song, Brian Xiaqing, West Chester, OH, UNITED STATES  
PA The Procter & Gamble Company (U.S. corporation)  
PI US 2002039982 A1 20020404  
AI US 2001-909403 A1 20010719 (9)  
PRAI WO 2000-US34907 20001221  
WO 2000-US19619 20000719  
WO 2000-US20255 20000725  
DT Utility  
FS APPLICATION  
LREP THE PROCTER & GAMBLE COMPANY, PATENT DIVISION, IVORYDALE TECHNICAL CENTER - BOX 474, 5299 SPRING GROVE AVENUE, CINCINNATI, OH, 45217

CLMN Number of Claims: 48  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1503

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A hard **surface** cleaning **composition** for removing cooked-, baked- or burnt-on soils from cookware and tableware, the **composition** comprising an organoamine solvent and wherein the **composition** has a liquid **surface** tension of less than about 24.5 mN/m and a pH, as measured in a 10% solution in distilled water, or least than 10.5. The **composition** can be used as pre-treatment prior to the dishwashing **process**. The **composition** provides excellent removal of polymerized grease from metal and glass substrates.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 36 OF 64 USPATFULL

AN 2002:67169 USPATFULL

TI Cleaning **composition**

IN Foley, Peter Robert, Cincinnati, OH, UNITED STATES  
Hutton, Howard David, III, Oregonia, OH, UNITED STATES  
Kaiser, Carl-Eric, Mason, OH, UNITED STATES  
Zhu, Yong, Cincinnati, OH, UNITED STATES  
Pieroni, Lucio, Hyogo, JAPAN  
Song, Brian Xiaqing, West Chester, OH, UNITED STATES

PI US 2002037822 A1 20020328

AI US 2001-910281 A1 20010719 (9)

PRAI WO 2000-US34906 20001221

WO 2000-US19619 20000719

WO 2000-US20255 20000725

DT Utility

FS APPLICATION

LREP THE PROCTER & GAMBLE COMPANY, PATENT DIVISION, IVORYDALE TECHNICAL CENTER - BOX 474, 5299 SPRING GROVE AVENUE, CINCINNATI, OH, 45217

CLMN Number of Claims: 50

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1559

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A hard **surface** cleaning **composition** for removing cooked-, baked- or burnt-on soils from cookware and tableware, the **composition** comprising a soil swelling agent and a spreading auxiliary and wherein the **composition** has a liquid **surface** tension of less than about 24.5 mN/m and a pH as measured in a 10% solution in distilled water of at least 10.5. The **composition** can be used as pre-treatment prior to the dishwashing **process**. The **composition** provides excellent removal of polymerized grease from metal and glass substrates.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 37 OF 64 USPATFULL

AN 2002:67164 USPATFULL

TI Cleaning **composition**

IN Foley, Peter Robert, Cincinnati, OH, UNITED STATES  
Hutton, Howard David, Oregonia, OH, UNITED STATES  
Kaiser, Carl-Eric, Mason, OH, UNITED STATES

PA The Procter & Gamble Company (U.S. corporation)

PI US 2002037817 A1 20020328

AI US 2001-909233 A1 20010719 (9)

PRAI WO 2000-US34907 20001221

WO 2000-US34906 20001221

WO 2000-US20255 20000725

WO 2000-US19619 20000719  
US 2001-268486P 20010213 (60)

DT Utility  
FS APPLICATION  
LREP THE PROCTER & GAMBLE COMPANY, PATENT DIVISION, IVORYDALE TECHNICAL  
CENTER - BOX 474, 5299 SPRING GROVE AVENUE, CINCINNATI, OH, 45217  
CLMN Number of Claims: 44  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1955

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A hard-**surface** cleaning **composition** for removing  
cooked-, baked-, or burnt-on food soil from cookware and tableware, the  
**composition** being in sprayable form and comprising an organic  
solvent system having a volatile organic content above 1 mm Hg of less  
than about 50% and an **odor** masking perfume or perfume base,  
said perfume or perfume base comprising at least about 20% by weight  
thereof of non-volatile perfume materials having a boiling point above  
250.**degree**. C. at 1 atmosphere pressure. The  
**composition** can be used as pre-treatment prior to the  
dishwashing **process**. The **composition** provides  
excellent removal of polymerized grease from metal and glass substrates  
and has a very pleasant **odor**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 38 OF 64 USPATFULL

AN 2002:27489 USPATFULL

TI Heterocyclic analgesic compounds and **methods** of use thereof

IN Cuny, Gregory D., Hudson, MA, UNITED STATES

Shao, Liming, Lincoln, MA, UNITED STATES

Hauske, James R., Concord, MA, UNITED STATES

Heffernan, Michele L.R., Worcester, MA, UNITED STATES

Aquila, Brian M., Marlborough, MA, UNITED STATES

Wu, Xinhe, Shrewsbury, MA, UNITED STATES

Wang, Fengjiang, Northborough, MA, UNITED STATES

Bannister, Thomas D., Northborough, MA, UNITED STATES

PI US 2002016337 A1 20020207

AI US 2001-798803 A1 20010302 (9)

RLI Continuation-in-part of Ser. No. US 2000-717174, filed on 20 Nov 2000,  
PENDING Continuation-in-part of Ser. No. US 2000-579398, filed on 25 May  
2000, PENDING

DT Utility

FS APPLICATION

LREP FOLEY, HOAG & ELIOT, LLP, PATENT GROUP, ONE POST OFFICE SQUARE, BOSTON,  
MA, 02109

CLMN Number of Claims: 26

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 6366

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to novel heterocyclic  
compounds. A second aspect of the present invention relates to the use  
of the novel heterocyclic compounds as ligands for various cellular  
receptors, including opiate receptors, other G-protein-coupled  
receptors, and ion channels. An additional aspect of the present  
invention relates to the use of the novel heterocyclic compounds as  
analgesics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 39 OF 64 USPATFULL

AN 2002:20752 USPATFULL

TI Stable, aqueous **compositions** for treating **surfaces**,



especially fabrics

IN Uchiyama, Hirotaka, Symmes Twp, OH, UNITED STATES  
 O'Brien Stickney, Janese Christine, Wyoming, OH, UNITED STATES  
 Cetti, Jonathan Robert, Fairfield, OH, UNITED STATES  
 Woo, Ricky Ah-Man, Hamilton, OH, UNITED STATES  
 DuVal, Dean Larry, Lebanon, OH, UNITED STATES  
 Frankenbach, Gayle Marie, Cincinnati, OH, UNITED STATES

PI US 2002011584 A1 20020131  
 US 6503413 B2 20030107

AI US 2001-783509 A1 20010214 (9)

PRAI US 2000-182381P 20000214 (60)  
 US 2000-240626P 20001016 (60)

DT Utility  
 FS APPLICATION  
 LREP THE PROCTER & GAMBLE COMPANY, PATENT DIVISION, IVORYDALE TECHNICAL  
 CENTER - BOX 474, 5299 SPRING GROVE AVENUE, CINCINNATI, OH, 45217

CLMN Number of Claims: 29  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 2941

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Stable, aqueous **compositions** for treating **surfaces**, especially fabrics, comprise: a relatively low molecular weight polyalkyleneoxide polysiloxane **surfactant**; a buffering agent to maintain the pH of the **composition** in the range of from about 4 to about 10, preferably from about 5 to about 9.5, and more preferably from about 6 to about 9; and an aqueous carrier. The **compositions** can further comprise cationic **surfactants** to further enhance the spreading and/or fabric penetration ability of the **compositions**. The **compositions** can further comprise a variety of other optional ingredients. **Methods** of treating **surfaces** include **methods** wherein the **compositions** are contacted with **surfaces**, especially fabrics, to reduce **malodor** impression on the **surfaces** and/or reduce the appearance of wrinkles in fabrics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 40 OF 64 USPATFULL  
 AN 2002:17438 USPATFULL  
 TI Secretory leukocyte protease inhibitor **dry powder** pharmaceutical **compositions**

IN Niven, Ralph W., Redwood City, CA, UNITED STATES  
 Wright, Clifford D., Boulder, CO, UNITED STATES  
 Chang, Byeong S., Thousand Oaks, CA, UNITED STATES

PA Amgen, Inc. (U.S. corporation)

PI US 2002010318 A1 20020124  
 AI US 2001-896685 A1 20010629 (9)

RLI Continuation of Ser. No. US 1997-943759, filed on 3 Oct 1997, PENDING

DT Utility  
 FS APPLICATION  
 LREP AMGEN INCORPORATED, MAIL STOP 27-4-A, ONE AMGEN CENTER DRIVE, THOUSAND  
 OAKS, CA, 91320-1799

CLMN Number of Claims: 25  
 ECL Exemplary Claim: 1  
 DRWN 12 Drawing Page(s)  
 LN.CNT 1992

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the pulmonary administration of a therapeutic protein by means of powdered pharmaceutical **compositions** suitable for inhalation therapy. In particular the invention relates to **dry powder** formulations of secretory leukocyte protease inhibitor (SLPI) for pulmonary delivery. Exemplary pharmaceutical **compositions** contain SLPI and a

pharmaceutically acceptable carrier in the form of a dry powder which is typically less than about 10% by weight water. About 50% to 95% by mass of the powder comprises particles or agglomerates of particles having a diameter within the range of from about 1.0 microns to about 8 microns, with a mass median diameter ranging from about 3.0 microns to about 6 microns.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 41 OF 64 USPATFULL  
AN 2002:17274 USPATFULL  
TI **Compositions comprising cyclodextrin**  
IN Uchiyama, Hirotaka, Symmes Twp, OH, UNITED STATES  
Woo, Ricky Ah-Man, Hamilton, OH, UNITED STATES  
DuVal, Dean Larry, Lebanon, OH, UNITED STATES  
Reece, Steven, West Chester, OH, UNITED STATES  
Stickney, Janese Christine O'apost, Brien, Wyoming, OH, UNITED STATES  
Cobb, Daniel Scott, Loveland, OH, UNITED STATES  
PI US 2002010154 A1 20020124  
AI US 2001-855337 A1 20010515 (9)  
PRAI US 2000-204162P 20000515 (60)  
DT Utility  
FS APPLICATION  
LREP THE PROCTER & GAMBLE COMPANY, PATENT DIVISION, IVORYDALE TECHNICAL  
CENTER - BOX 474, 5299 SPRING GROVE AVENUE, CINCINNATI, OH, 45217  
CLMN Number of Claims: 52  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2249

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A stable **composition** for removing unwanted molecules from a **surface** comprises functionally-available **cyclodextrin** and **cyclodextrin-compatible surfactant**, wherein the **cyclodextrin-compatible surfactant** is selected from the group consisting of castor oil **surfactant**, sorbitan ester **surfactant**, polyethoxylated fatty alcohol **surfactant**, polypropoxylated fatty alcohol **surfactant**, glycerol mono-fatty acid ester **surfactant**, polyethylene glycol fatty acid ester **surfactant**, polypropylene glycol fatty acid ester **surfactant**, fluorocarbon **surfactant**, and **mixtures** thereof. The **compositions** are suitable for **capturing** unwanted molecules from inanimate **surfaces**, including fabrics, including carpets, and household **surfaces** such as countertops, dishes, floors, garbage cans, ceilings, walls, carpet padding, air filters, and the like, and from animate **surfaces**, including skin, hair, and the like. The **compositions** can further comprise other **cyclodextrin-compatible** and -**incompatible** materials and other optional ingredients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 42 OF 64 USPATFULL  
AN 2002:17226 USPATFULL  
TI **Compositions comprising cyclodextrin**  
IN Uchiyama, Hirotaka, Symmes Twp., OH, UNITED STATES  
Woo, Ricky Ah-Man, Hamilton, OH, UNITED STATES  
DuVal, Dean Larry, Lebanon, OH, UNITED STATES  
Reece, Steven, West Chester, OH, UNITED STATES  
PI US 2002010106 A1 20020124  
AI US 2001-855816 A1 20010515 (9)  
PRAI US 2000-204161P 20000515 (60)  
DT Utility  
FS APPLICATION

LREP THE PROCTER & GAMBLE COMPANY, PATENT DIVISION, IVORYDALE TECHNICAL  
CENTER - BOX 474, 5299 SPRING GROVE AVENUE, CINCINNATI, OH, 45217  
CLMN Number of Claims: 59  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1792

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A stable **composition** for removing unwanted molecules from a  
**surface** comprises functionally-available **cyclodextrin**  
and **cyclodextrin-incompatible** material, wherein the  
**cyclodextrin-incompatible** material is not a perfume  
material. The **compositions** are suitable for **capturing**  
unwanted molecules from inanimate **surfaces**, including fabrics,  
including carpets, and household **surfaces** such as countertops,  
dishes, floors, garbage cans, ceilings, walls, carpet padding, air  
filters, and the like, and from animate **surfaces**, including  
skin, hair, and the like. The **compositions** can further  
comprise **cyclodextrin-compatible** materials and other  
optional ingredients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 43 OF 64 USPATFULL

AN 2002:12672 USPATFULL

TI **Compositions** comprising **cyclodextrin**

IN Uchiyama, Hirotaka, Symmes Twp., OH, UNITED STATES

Woo, Ricky Ah-Man, Hamilton, OH, UNITED STATES

DuVal, Dean Larry, Lebanon, OH, UNITED STATES

Reece, Steven, West Chester, OH, UNITED STATES

PI US 2002007055 A1 20020117

AI US 2001-855440 A1 20010515 (9)

PRAI US 2000-204163P 20000515 (60)

DT Utility

FS APPLICATION

LREP THE PROCTER & GAMBLE COMPANY, PATENT DIVISION, IVORYDALE TECHNICAL  
CENTER - BOX 474, 5299 SPRING GROVE AVENUE, CINCINNATI, OH, 45217

CLMN Number of Claims: 52

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1942

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A stable **composition** for removing unwanted molecules from a  
**surface** comprises functionally-available **cyclodextrin**,  
**cyclodextrin-compatible** surfactant, and  
**cyclodextrin-incompatible** surfactant. The  
**compositions** are suitable for **capturing** unwanted  
molecules from inanimate **surfaces**, including fabrics,  
including carpets, and hard **surfaces** including countertops,  
dishes, floors, garbage cans, ceilings, walls, carpet padding, air  
filters, and the like, and from animate **surfaces**, including  
skin, hair, and the like. The **compositions** can further  
comprise other **cyclodextrin-compatible** and -  
**incompatible** materials and other optional ingredients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 44 OF 64 USPATFULL

AN 2001:237970 USPATFULL

TI 3-substituted piperidines comprising urea functionality, and  
**methods** of use thereof

IN Aquila, Brian M., Marlborough, MA, United States

Cuny, Gregory D., Hudson, MA, United States

Hauske, James R., Concord, MA, United States

Shao, Liming, Lincoln, MA, United States

Wu, Xinhe, Shrewsbury, MA, United States  
PI US 2001056090 A1 20011227  
US 6476050 B2 20021105  
AI US 2001-792866 A1 20010223 (9)  
PRAI US 2000-189349P 20000314 (60)  
DT Utility  
FS APPLICATION  
LREP FOLEY, HOAG & ELIOT, LLP, PATENT GROUP, ONE POST OFFICE SQUARE, BOSTON,  
MA, 02109  
CLMN Number of Claims: 52  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Page(s)  
LN.CNT 2807  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB One aspect of the present invention relates to novel heterocyclic  
compounds comprising urea functionality. A second aspect of the present  
invention relates to the use of the novel heterocyclic compounds  
comprising urea functionality as ligands for various cellular receptors,  
including opioid receptors, other G-protein-coupled receptors and ion  
channels. An additional aspect of the present invention relates to the  
use of the novel heterocyclic compounds comprising urea functionality as  
analgesics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 45 OF 64 USPATFULL  
AN 2001:237960 USPATFULL  
TI **Compositions** comprising **cyclodextrin** derivatives  
IN Woo, Ricky Ah-Man, Hamilton, OH, United States  
Uchiyama, Hirotaka, Symmes Twp, OH, United States  
Reece, Steven, West Chester, OH, United States  
DuVal, Dean Larry, Lebanon, OH, United States  
Schaeffer, Heather Ann, Loveland, OH, United States  
PI US 2001056080 A1 20011227  
AI US 2001-855329 A1 20010515 (9)  
PRAI US 2000-204164P 20000515 (60)  
DT Utility  
FS APPLICATION  
LREP THE PROCTER & GAMBLE COMPANY, PATENT DIVISION, IVORYDALE TECHNICAL  
CENTER - BOX 474, 5299 SPRING GROVE AVENUE, CINCINNATI, OH, 45217  
CLMN Number of Claims: 16  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1971  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB A stable **composition** for removing unwanted molecules from a  
**surface** comprises low-degree of **substitution**  
**cyclodextrin** derivatives. The **compositions** are  
suitable for **capturing** unwanted molecules from inanimate  
**surfaces**, including fabrics, including carpets, and household  
**surfaces** such as countertops, dishes, floors, garbage cans,  
ceilings, walls, carpet padding, air filters, and the like, and from  
animate **surfaces**, including skin, hair, and the like. The  
**compositions** can further comprise **cyclodextrin-**  
**compatible** and **-incompatible** materials, and other  
optional ingredients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 46 OF 64 USPATFULL  
AN 2001:212546 USPATFULL  
TI Imaging agents for diagnosis of Parkinson's disease  
IN Babich, John W., North Scituate, MA, United States  
Smith, Miles P., Belmont, MA, United States

PI US 2001044543 A1 20011122  
US 6515131 B2 20030204  
AI US 2001-790320 A1 20010222 (9)  
PRAI US 2000-183996P 20000222 (60)  
DT Utility  
FS APPLICATION  
LREP FOLEY, HOAG & ELIOT, LLP, PATENT GROUP, ONE POST OFFICE SQUARE, BOSTON,  
MA, 02109  
CLMN Number of Claims: 164  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2656

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Generally, the present invention is directed to central nervous system dopamine transporter-imaging agents and **methods** of use thereof. In certain embodiments, the present invention relates to radiolabeled piperidine derivatives for use as imaging agents in the diagnosis of Parkinson's disease. Another aspect of the present invention relates to piperidine monoamine transporter ligands, comprising a functional group capable of chelating a radionuclide, e.g., technetium, and **methods** of use thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 47 OF 64 USPATFULL  
AN 2001:188700 USPATFULL  
TI **Cyclodextrin** polymer **compositions** for use as drug carriers  
IN Kosak, Kenneth M., West Valley City, UT, United States  
PI US 2001034333 A1 20011025  
AI US 2001-775011 A1 20010201 (9)  
RLI Continuation-in-part of Ser. No. WO 1999-US30820, filed on 27 Dec 1999, UNKNOWN Continuation-in-part of Ser. No. US 1998-223055, filed on 30 Dec 1998, GRANTED, Pat. No. US 6048736  
DT Utility  
FS APPLICATION  
LREP KENNETH M. KOSAK, 3194 S. 4400 W., West Valley City, UT, 84120  
CLMN Number of Claims: 23  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2761

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention discloses **compositions** of **cyclodextrin** polymers for carrying drugs and other active agents. **Compositions** are also disclosed of **cyclodextrin** polymer carriers that release drugs under controlled conditions. The invention also discloses **compositions** of **cyclodextrin** polymer carriers that are coupled to biorecognition molecules for targeting the delivery of drugs to their site of action.

The advantages of the water-soluble **cyclodextrin** polymer carrier are:

- (1) Drugs can be used based on efficacy without solubility or conjugation requirements.
- (2) Drugs can be delivered as macromolecules and released within the cell.
- (3) Drugs can be targeted by coupling the carrier to biorecognition molecules.
- (4) Synthesis **methods** are independent of the drug to facilitate multiple drug therapies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 48 OF 64 USPATFULL  
AN 2001:155769 USPATFULL  
TI Biocleavable **micelle compositions** for use as drug carriers  
IN Kosak, Kenneth M., West Valley City, UT, United States  
PI US 2001021703 A1 20010913  
AI US 2001-829551 A1 20010410 (9)  
RLI Continuation-in-part of Ser. No. WO 1999-US30820, filed on 27 Dec 1999, UNKNOWN Continuation-in-part of Ser. No. US 1998-223055, filed on 30 Dec 1998, GRANTED, Pat. No. US 6048736  
DT Utility  
FS APPLICATION  
LREP KENNETH M. KOSAK, 3194 S. 4400 W., West Valley City, UT, 84120  
CLMN Number of Claims: 20  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1789

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention discloses **compositions** and **methods** for preparing biocleavable or biodegradable **micelle compositions** for carrying and releasing drugs and other active agents for therapeutic or other medical uses. **Methods** are also disclosed for preparing biocleavable **cyclodextrin micelle** carriers that release drugs under controlled conditions.

The invention also discloses biocleavable or biodegradable **micelle compositions** that are coupled to biorecognition molecules for targeting the delivery of drugs to their site of action.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 49 OF 64 USPATFULL  
AN 2001:105320 USPATFULL  
TI SECRETORY LEUKOCYTE PROTEASE INHIBITOR DRY POWDER PHARMACEUTICAL **COMPOSITIONS**  
IN NIVEN, RALPH W., REDWOOD CITY, CA, United States  
WRIGHT, CLIFFORD D., BOULDER, CO, United States  
CHANG, BYEONG S., THOUSAND OAKS, CA, United States  
PI US 2001006939 A1 20010705  
AI US 1997-943759 A1 19971003 (8)  
DT Utility  
FS APPLICATION  
LREP AMGEN INCORPORATED, MAIL STOP 27-4-A, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799  
CLMN Number of Claims: 25  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Page(s)  
LN.CNT 1989

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the pulmonary administration of a therapeutic protein by means of powdered pharmaceutical **compositions** suitable for inhalation therapy. In particular the invention relates to **dry** powder formulations of secretory leukocyte protease inhibitor (SLPI) for pulmonary delivery. Exemplary pharmaceutical **compositions** contain SLPI and a pharmaceutically acceptable carrier in the form of a **dry** powder which is typically less than about 10% by weight water. About 50% to 95% by mass of the powder comprises particles or agglomerates of particles having a diameter within the range of from about 1.0 microns to about 8 microns, with a mass median diameter ranging from about 3.0

microns to about 6 microns.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 50 OF 64 USPATFULL  
AN 2001:93131 USPATFULL  
TI Solid carriers for improved delivery of active ingredients in  
pharmaceutical **compositions**  
IN Patel, Mahesh V., Salt Lake City, UT, United States  
Chen, Feng-Jing, Salt Lake City, UT, United States  
PA Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)  
PI US 6248363 B1 20010619  
AI US 1999-447690 19991123 (9)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Spear, James M.  
LREP Reed, Dianne E. Reed & Associates  
CLMN Number of Claims: 57  
ECL Exemplary Claim: 1  
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)  
LN.CNT 3302

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides solid pharmaceutical **compositions** for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical **composition** includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic **surfactant**, lipophilic **surfactants** and triglycerides. In another embodiment, the solid pharmaceutical **composition** includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic **surfactants**, lipophilic **surfactants** and triglycerides. The **compositions** of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutrionals, cosmeceuticals and diagnostic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 51 OF 64 USPATFULL  
AN 2001:71071 USPATFULL  
TI **Methods** for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same  
IN Unger, Evan C., Tucson, AZ, United States  
Fritz, Thomas A., Tucson, AZ, United States  
Gertz, Edward W., Paradise Valley, AZ, United States  
PA ImaRx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)  
PI US 6231834 B1 20010515  
AI US 1997-982829 19971202 (8)  
RLI Continuation-in-part of Ser. No. US 1997-932273, filed on 17 Sep 1997  
Continuation-in-part of Ser. No. US 1996-666129, filed on 19 Jun 1996, now patented, Pat. No. US 6033645  
Continuation-in-part of Ser. No. US 1996-660032, filed on 6 Jun 1996, now abandoned  
Continuation-in-part of Ser. No. US 1996-640464, filed on 1 May 1996, now abandoned  
Continuation-in-part of Ser. No. US 1995-497684, filed on 7 Jun 1995, now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Hollinden, Gary E.  
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP  
CLMN Number of Claims: 115  
ECL Exemplary Claim: 1

DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 7574

AB Improved **methods** for providing an image of an internal region of a patient. Embodiments of the invention involve the administration to the patient of a contrast agent which comprises, in an aqueous carrier, a lipid, protein, polymer or **surfactant**, and a gas. The patient is scanned using ultrasound imaging to obtain a visible image of the region. In embodiments of the invention, the scanning step may comprise applying a first quantity of ultrasound energy to the patient to provide a first image, followed by the application substantially immediately thereafter of a second quantity of ultrasound energy to provide a second image. The first and second images are then processed. The **methods** are particularly useful for obtaining on-line images of the cardiovascular region which may be employed, for example, to diagnose the presence of diseased tissue in the cardiovascular region of a patient.

L11 ANSWER 52 OF 64 USPATFULL

AN 2000:145865 USPATFULL

TI Targeted contrast agents for diagnostic and therapeutic use

IN Unger, Evan C., Tucson, AZ, United States

Fritz, Thomas A., Tucson, AZ, United States

Gertz, Edward W., Paradise Valley, AZ, United States

PA ImaRx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)

PI US 6139819 20001031

AI US 1997-932273 19970917 (8)

RLI Continuation-in-part of Ser. No. US 1996-660032, filed on 6 Jun 1996, now abandoned which is a continuation-in-part of Ser. No. US 1996-640464, filed on 1 May 1996, now abandoned which is a continuation-in-part of Ser. No. US 1995-497684, filed on 7 Jun 1995, now abandoned And a continuation-in-part of Ser. No. US 1996-666129, filed on 19 Jun 1996, now patented, Pat. No. US 6033645

DT Utility

FS Granted

EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Hartley, Michael G.

LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP

CLMN Number of Claims: 174

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 7523

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel contrast agents which may be used for diagnostic and therapeutic use. The **compositions** may comprise a lipid, a protein, polymer and/or **surfactant**, and a gas, in combination with a targeting ligand. In preferred embodiments, the targeting ligand targets coagula, including emboli and/or thrombi, particularly in patients suffering from an arrhythmic disorder. The contrast media can be used in conjunction with diagnostic imaging, such as ultrasound, as well as therapeutic applications, such as therapeutic ultrasound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 53 OF 64 USPATFULL

AN 2000:43976 USPATFULL

TI **Cyclodextrin** polymers for carrying and releasing drugs

IN Kosak, Kenneth M., 3194 S. 4400 West, West Valley City, UT, United States 84120

PI US 6048736 20000411

AI US 1998-223055 19981230 (9)

RLI Continuation-in-part of Ser. No. US 1998-67921, filed on 29 Apr 1998, now abandoned

DT Utility





R2 is a lipophilic radical and  
the MS for R1 is 0.3 to 2.0 and  
the MS for R2 is 0.2 to 1.0 and  
n is 6, 7, or 8.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 55 OF 64 USPATFULL  
AN 93:67317 USPATFULL  
TI Solid, particulate detergent **composition** with protected,  
dryer-activated, water sensitive material  
IN Trinh, Toan, Maineville, OH, United States  
Bacon, Dennis R., Milford, OH, United States  
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S.  
corporation)  
PI US 5236615 19930817  
AI US 1991-751401 19910828 (7)  
DCD 20100803  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Lieberman, Paul; Assistant Examiner: Parks, William S.  
LREP Aylor, Robert B.  
CLMN Number of Claims: 10  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1531

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Fabric softening **compositions**, preferably in liquid form, for  
use in the rinse cycle of home laundry operations are improved by: (a)  
using certain protected water sensitive materials, especially  
particulate complexes of **cyclodextrins** and perfumes, which are  
protected in fabric softening **compositions** and/or detergent  
**compositions**, by e.g., imbedding said particulate complex in  
relatively high melting protective material that is substantially  
water-insoluble and, preferably, non-water-swellable and is solid at  
normal storage conditions, but which melts at the temperatures  
encountered in automatic fabric dryers (laundry dryers); (b) using soil  
release polymers to help suspend water-insoluble particles in aqueous  
fabric softening **compositions**; and/or (c) preparing the said  
protected particulate water sensitive materials (complexes) by melting  
the said high melting materials, dispersing the said particulate  
complexes, or other water sensitive material, in the molten high melting  
protective material and dispersing the resulting molten **mixture**  
in aqueous media, especially **surfactant** solution or aqueous  
fabric softener **composition**, and cooling to form small,  
smooth, spherical particles of the particulate complexes, or other water  
sensitive material, substantially protected by the high melting  
material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 56 OF 64 USPATFULL  
AN 93:65086 USPATFULL  
TI Fabric softener, preferably liquid, with protected, dryer-activated,  
**cyclodextrin**/perfume complex  
IN Trinh, Toan, Maineville, OH, United States  
Bacon, Dennis R., Milford, OH, United States  
Benvegnu, Fernando, Maineville, OH, United States  
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S.  
corporation)  
PI US 5234611 19930810

AI US 1991-751351 19910828 (7)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: McFarlane, Anthony  
LREP Aylor, Robert B.  
CLMN Number of Claims: 22  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1572

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Fabric softening **compositions**, preferably in liquid form, for use in the rinse cycle of home laundry operations are improved by: (a) using certain protected water sensitive materials, especially particulate complexes of **cyclodextrins** and perfumes, which are protected in fabric softening **compositions** and/or detergent **compositions**, by e.g., imbedding said particulate complex in relatively high melting protective material that is substantially water-insoluble and, preferably, non-water-swellaable and is solid at normal storage conditions, but which melts at the temperatures encountered in automatic fabric dryers (laundry dryers); (b) using soil release polymers to help suspend water-insoluble particles in aqueous fabric softening **compositions**; and/or (c) preparing the said protected particulate water sensitive materials (complexes) by melting the said high melting materials, dispersing the said particulate complexes, or other water sensitive material, in the molten high melting protective material and dispersing the resulting molten **mixture** in aqueous media, especially **surfactant** solution or aqueous fabric softener **composition**, and cooling to form small, smooth, spherical particles of the particulate complexes, or other water sensitive material, substantially protected by the high melting material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 57 OF 64 USPATFULL

AN 93:62860 USPATFULL

TI **Process** for preparing protected particles of water sensitive material

IN Bacon, Dennis R., Milford, OH, United States

Trinh, Toan, Maineville, OH, United States

PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

PI US 5232613 19930803

AI US 1991-751403 19910828 (7)

DT Utility

FS Granted

EXNAM Primary Examiner: Chaudhuri, Olik; Assistant Examiner: Everhart, C.

LREP Aylor, Robert B.

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1520

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Fabric softening **compositions**, preferably in liquid form, for use in the rinse cycle of home laundry operations are improved by: (a) using certain protected water sensitive materials, especially particulate complexes of **cyclodextrins** and perfumes, which are protected in fabric softening **compositions** and/or detergent **compositions**, by e.g., imbedding said particulate complex in relatively high melting protective material that is substantially water-insoluble and, preferably, non-water-swellaable and is solid at normal storage conditions, but which melts at the temperatures encountered in automatic fabric dryers (laundry dryers); (b) using soil release polymers to help suspend water-insoluble particles in aqueous

fabric softening **compositions**; and/or (c) preparing the said protected particulate water sensitive materials (complexes) by melting the said high melting materials, dispersing the said particulate complexes, or other water sensitive material, in the molten high melting protective material and dispersing the resulting molten **mixture** in aqueous media, especially **surfactant** solution or aqueous fabric softener **composition**, and cooling to form small, smooth, spherical particles of the particulate complexes, or other water sensitive material, substantially protected by the high melting material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 58 OF 64 USPATFULL  
AN 93:35387 USPATFULL  
TI Liquid fabric softener with insoluble particles stably suspended by soil release polymer  
IN Trinh, Toan, Maineville, OH, United States  
Tordil, Helen B., West Chester, OH, United States  
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)  
PI US 5207933 19930504  
AI US 1991-751427 19910828 (7)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Chaudhuri, Olik; Assistant Examiner: Everhart, C.  
LREP Aylor, Robert B.  
CLMN Number of Claims: 11  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 1531

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Fabric softening **compositions**, preferably in liquid form, for use in the rinse cycle of home laundry operations are improved by: (a) using certain protected water sensitive materials, especially particulate complexes of **cyclodextrins** and perfumes, which are protected in fabric softening **compositions** and/or detergent **compositions**, by e.g., imbedding said particulate complex in relatively high melting protective material that is substantially water-insoluble and, preferably, non-water-swellaable and is solid at normal storage conditions, but which melts at the temperatures encountered in automatic fabric dryers (laundry dryers); (b) using soil release polymers to help suspend water-insoluble particles in aqueous fabric softening **compositions**; and/or (c) preparing the said protected particulate water sensitive materials (complexes) by melting the said high melting materials, dispersing the said particulate complexes, or other water sensitive material, in the molten high melting protective material and dispersing the resulting molten **mixture** in aqueous media, especially **surfactant** solution or aqueous fabric softener **composition**, and cooling to form small, smooth, spherical particles of the particulate complexes, or other water sensitive material, substantially protected by the high melting material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 59 OF 64 USPAT2  
AN 2002:330424 USPAT2  
TI Phthalamide lanthanide complexes for use as luminescent markers  
IN Raymond, Kenneth N., Berkeley, CA, United States  
Petoud, Stephane, Berkeley, CA, United States  
Cohen, Seth M., Boston, MA, United States  
Xu, Jide, Berkeley, CA, United States  
PA The Regents of the University of California, Oakland, CA, United States

(U.S. corporation)  
PI US 6515113 B2 20030204  
AI US 2000-507630 20000218 (9)  
PRAI US 1999-120881P 19990218 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Ceperley, Mary E.  
LREP Townsend and Townsend and Crew LLP  
CLMN Number of Claims: 5  
ECL Exemplary Claim: 1  
DRWN 23 Drawing Figure(s); 23 Drawing Page(s)  
LN.CNT 3825

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides luminescent lanthanide metal chelates comprising a metal ion of the lanthanide series and a complexing agent comprising at least one phthalamidyl moiety. Also provided are probes incorporating the phthalamidyl ligands of the invention and **methods** utilizing the ligands of the invention and probes comprising the ligands of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 60 OF 64 USPAT2  
AN 2002:283360 USPAT2  
TI Keratinocyte derived interferon  
IN LaFleur, David W., Washington, DC, UNITED STATES  
Moore, Paul A., Germantown, MD, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
PI US 2002187950 A1 20021212  
AI US 2001-908594 A1 20010720 (9)  
RLI Continuation-in-part of Ser. No. US 2000-487792, filed on 20 Jan 2000, PENDING Continuation-in-part of Ser. No. WO 2000-US1239, filed on 20 Jan 2000, UNKNOWN Continuation-in-part of Ser. No. US 2000-487792, filed on 20 Jan 2000, PENDING Continuation-in-part of Ser. No. US 1999-358587, filed on 21 Jul 1999, ABANDONED Continuation-in-part of Ser. No. WO 1999-US16424, filed on 21 Jul 1999, UNKNOWN Continuation-in-part of Ser. No. WO 2000-US1239, filed on 20 Jan 2000, UNKNOWN Continuation of Ser. No. US 1999-358587, filed on 21 Jul 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-358587, filed on 21 Jul 1999, ABANDONED  
PRAI WO 1999-US16424 19990721  
US 2001-292934P 20010524 (60)  
US 2000-219621P 20000721 (60)  
US 1998-93643P 19980721 (60)  
US 1998-93643P 19980721 (60)  
DT Utility  
FS APPLICATION  
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850  
CLMN Number of Claims: 40  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Page(s)  
LN.CNT 14630

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel KDI protein which is a member of the interferon family. In particular, isolated nucleic acid molecules are provided encoding a human interferon polypeptide, called "KDI". KDI polypeptides are also provided as are vectors, host cells and recombinant **methods** for producing the same. The invention further relates to screening **methods** for identifying agonists and antagonists of KDI activity. Also provided are therapeutic **methods** for treating immune system-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 61 OF 64 USPAT2

AN 2002:280646 USPAT2  
TI Diazabicyclo[4.3.0]nonanes, and **methods** of use thereof  
IN Wu, Xinhe, Shrewsbury, MA, United States  
PA Sepracor, Inc., Marlborough, MA, United States (U.S. corporation)  
PI US 6476046 B2 20021105  
AI US 2001-21277 20011030 (10)  
PRAI US 2000-251108P 20001204 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Dentz, Bernard  
LREP Gordon, Dana M., Foley Hoag LLP  
CLMN Number of Claims: 36  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 3048  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB One aspect of the present invention relates to diazabicyclo[4.3.0]nonanes. A second aspect of the present invention relates to the use of the diazabicyclo[4.3.0]nonanes as ligands for various cellular receptors, including opiate receptors. An additional aspect of the present invention relates to the use of the diazabicyclo[4.3.0]nonanes as analgesics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 62 OF 64 USPAT2  
AN 2002:20752 USPAT2  
TI Stable, aqueous **compositions** for treating **surfaces**, especially fabrics  
IN Uchiyama, Hirotaka, Symmes Twp, OH, United States  
Stickney, Janese Christine O'Brien, Wyoming, OH, United States  
Cetti, Jonathan Robert, Fairfield, OH, United States  
Woo, Ricky Ah-Man, Hamilton, OH, United States  
DuVal, Dean Larry, Lebanon, OH, United States  
Frankenbach, Gayle Marie, Cincinnati, OH, United States  
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)  
PI US 6503413 B2 20030107  
AI US 2001-783509 20010214 (9)  
RLI Continuation-in-part of Ser. No. US 2000-634379, filed on 9 Aug 2000  
PRAI US 2000-240626P 20001016 (60)  
US 2000-182381P 20000214 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Green, Anthony J.  
LREP Bamber, Jeffrey V., Camp, Jason J.  
CLMN Number of Claims: 29  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 2876  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Stable, aqueous **compositions** for treating **surfaces**, especially fabrics, comprise: a relatively low molecular weight polyalkyleneoxide polysiloxane **surfactant**; a buffering agent to maintain the pH of the **composition** in the range of from about 4 to about 10, preferably from about 5 to about 9.5, and more preferably from about 6 to about 9; and an aqueous carrier. The **compositions** can further comprise cationic **surfactants** to further enhance the spreading and/or fabric penetration ability of the **compositions**. The **compositions** can further comprise a variety of other optional ingredients. **Methods** of treating **surfaces** include **methods** wherein the **compositions** are contacted with **surfaces**, especially fabrics, to reduce **malodor** impression on the **surfaces**

and/or reduce the appearance of wrinkles in fabrics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 63 OF 64 USPAT2  
AN 2001:237970 USPAT2  
TI 3-substituted piperidines comprising urea functionality, and  
methods of use thereof  
IN Aquila, Brian M., Marlborough, MA, United States  
Cuny, Gregory D., Hudson, MA, United States  
Hauske, James R., Concord, MA, United States  
Shao, Liming, Lincoln, MA, United States  
Wu, Xinhe, Marlborough, MA, United States  
PA Sepracor, Inc., Marlborough, MA, United States (U.S. corporation)  
PI US 6476050 B2 20021105  
AI US 2001-792866 20010223 (9)  
PRAI US 2000-189349P 20000314 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Rao, Deepak R.; Assistant Examiner: Liu, Hong  
LREP Gordon, Dana M., Foley Hoag LLP  
CLMN Number of Claims: 8  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)  
LN.CNT 2673

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to novel heterocyclic compounds comprising urea functionality. A second aspect of the present invention relates to the use of the novel heterocyclic compounds comprising urea functionality as ligands for various cellular receptors, including opioid receptors, other G-protein-coupled receptors and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds comprising urea functionality as analgesics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 64 OF 64 USPAT2  
AN 2001:212546 USPAT2  
TI Imaging agents for diagnosis of Parkinson's disease  
IN Babich, John W., North Scituate, MA, United States  
Smith, Miles P., Belmont, MA, United States  
PA Biostream Therapeutics, Inc., Cambridge, MA, United States (U.S. corporation)  
PI US 6515131 B2 20030204  
AI US 2001-790320 20010222 (9)  
PRAI US 2000-183996P 20000222 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Chang, Ceila  
LREP Gordon, Dana M., Foley Hoag LLP  
CLMN Number of Claims: 56  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 2542

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Generally, the present invention is directed to central nervous system dopamine transporter-imaging agents and methods of use thereof. In certain embodiments, the present invention relates to radiolabeled piperidine derivatives for use as imaging agents in the diagnosis of Parkinson's disease. Another aspect of the present invention relates to piperidine monoamine transporter ligands, comprising a functional group capable of chelating a radionuclide, e.g., technetium, and methods of use thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> dis hist

(FILE 'HOME' ENTERED AT 07:33:34 ON 24 FEB 2003)

FILE 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, EMA, IFIPAT, JICST-EPLUS,  
PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL,  
USPAT2, WPINDEX, WTEXTILES' ENTERED AT 07:33:47 ON 24 FEB 2003

L1	4548373 S COMPOSITION
L2	12915 S L1 AND CYCLODEXTRIN
L3	2457 S L2 AND (SUBSTITUTION AND DEGREE)
L4	1850 S L3 AND (ALKYL OR HYDROXYALKYL)
L5	1766 S L4 AND (ALPHA OR BETA OR GAMMA)
L6	621 S L5 AND (CAPTUR? OR ODOR OR MALODOR)
L7	621 S L6 AND (PROCESS OR MANUFACTUR? OR METHOD OR MAKING)
L8	548 S L7 AND (SURFACTANT OR COMPATIBLE OR INCOMPATIBLE)
L9	540 S L8 AND MIXTURE
L10	64 S L9 AND (MICELLE OR VESCILE)
L11	64 S L10 AND (SURFACE OR APPLY OR DRY)